News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Principal investigator of Aladote® study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference

October 4, 2017

PledPharma AB
Company Announcement

Principal investigator of Aladote® study James Dear presents calmangafodipir as
a potential new treatment for late stage liver toxicity after acetaminophen
overdose at liver disease conference

Stockholm, 2017-10-04 09:05 CEST (GLOBE NEWSWIRE) -- 

PledPharma announces that an abstract presenting preclinical data for
calmangafodipir has been accepted for presentation at a major international
liver meeting in Washington DC during October 20-24, 2017. 

The work was a collaboration between Dr. James Dear and his group at the
University of Edinburgh and PledPharma. The abstract, “Calmangafodipir is a new
treatment for late stage liver toxicity after acetaminophen overdose”, has
received acceptance for presentation of results from the preclinical study and
the design of the ongoing clinical study at the 68th Annual Meeting of AASLD*,
October 20-24, 2017 in Washington, DC, USA. The presentation will cover
preclinical data indicating that calmangafodipir could be used as an effective
treatment for acetaminophen poisoning in patients who present late to hospital
when standard of care antidote (acetylcysteine, NAC) has lost efficacy. 

Based on the preclinical data, a proof of principle study with the focus on
safety and tolerability in patients attending hospital following an
acetaminophen overdose has started at the Edinburgh Royal Infirmary and the
first patient was included in June. 

“The fact that the Abstract has been selected for presentation at the liver
meeting underlines the importance of the interesting pre-clinical data for
calmangafodipir as a potential new treatment modality for acetaminophen
(paracetamol) overdose patients and illustrates the growing interest in
treating this patient group.” says Nicklas Westerholm, CEO PledPharma 

AASLD information:
Session ID: Parallel Session 1
Session Title: Drug and Herbal Induced Liver Injury
Session Date and Time: Oct 22, 2017 8:00 AM - 9:30 AM
Abstract Number: 14

*AASLD stands for the American Association for the Study of Liver Diseases.
AASLD is referred to “The Liver Meeting”. 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62
[email protected]

Michaela Gertz, CFO, phone: +46 709 26 17 75
[email protected]

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see www.pledpharma.se

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]